Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 11 studies | 40% ± 22% | |
fibroblast | 11 studies | 60% ± 25% | |
connective tissue cell | 8 studies | 67% ± 23% | |
pericyte | 6 studies | 32% ± 22% | |
endothelial cell of artery | 5 studies | 39% ± 28% | |
epithelial cell | 4 studies | 57% ± 14% | |
mesothelial cell | 4 studies | 64% ± 17% | |
myofibroblast cell | 3 studies | 64% ± 21% | |
vein endothelial cell | 3 studies | 48% ± 19% | |
basal cell | 3 studies | 38% ± 28% |
Insufficient scRNA-seq data for expression of IGF2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
adrenal gland | 95% | 7647.83 | 246 / 258 | 93% | 95.70 | 213 / 230 |
ovary | 97% | 7807.84 | 174 / 180 | 75% | 115.89 | 322 / 430 |
breast | 99% | 8668.26 | 454 / 459 | 41% | 2.68 | 457 / 1118 |
bladder | 95% | 4588.57 | 20 / 21 | 38% | 19.13 | 189 / 504 |
liver | 100% | 17671.13 | 226 / 226 | 27% | 30.70 | 108 / 406 |
uterus | 95% | 11180.75 | 161 / 170 | 23% | 10.17 | 106 / 459 |
esophagus | 72% | 2843.52 | 1037 / 1445 | 35% | 4.69 | 64 / 183 |
intestine | 72% | 3043.60 | 696 / 966 | 31% | 18.93 | 163 / 527 |
ureter | 0% | 0 | 0 / 0 | 100% | 3.79 | 1 / 1 |
adipose | 100% | 15370.39 | 1203 / 1204 | 0% | 0 | 0 / 0 |
heart | 99% | 7982.34 | 855 / 861 | 0% | 0 | 0 / 0 |
muscle | 96% | 5556.60 | 770 / 803 | 0% | 0 | 0 / 0 |
kidney | 73% | 4456.60 | 65 / 89 | 10% | 5.37 | 93 / 901 |
stomach | 38% | 1866.55 | 137 / 359 | 45% | 35.86 | 129 / 286 |
blood vessel | 82% | 4628.58 | 1089 / 1335 | 0% | 0 | 0 / 0 |
thymus | 78% | 2436.60 | 512 / 653 | 3% | 1.38 | 18 / 605 |
lung | 48% | 1544.77 | 278 / 578 | 20% | 7.12 | 232 / 1155 |
prostate | 66% | 2490.84 | 161 / 245 | 2% | 0.72 | 9 / 502 |
skin | 48% | 3019.59 | 864 / 1809 | 8% | 0.68 | 38 / 472 |
pancreas | 27% | 835.87 | 88 / 328 | 25% | 2.43 | 44 / 178 |
spleen | 37% | 898.14 | 89 / 241 | 0% | 0 | 0 / 0 |
brain | 14% | 292.28 | 366 / 2642 | 10% | 2.19 | 67 / 705 |
tonsil | 0% | 0 | 0 / 0 | 13% | 0.33 | 6 / 45 |
peripheral blood | 6% | 216.75 | 53 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 1% | 0.02 | 1 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0042104 | Biological process | positive regulation of activated T cell proliferation |
GO_0051781 | Biological process | positive regulation of cell division |
GO_0001701 | Biological process | in utero embryonic development |
GO_0001892 | Biological process | embryonic placenta development |
GO_0051147 | Biological process | regulation of muscle cell differentiation |
GO_0001649 | Biological process | osteoblast differentiation |
GO_0048009 | Biological process | insulin-like growth factor receptor signaling pathway |
GO_0009887 | Biological process | animal organ morphogenesis |
GO_0060669 | Biological process | embryonic placenta morphogenesis |
GO_0051148 | Biological process | negative regulation of muscle cell differentiation |
GO_0071514 | Biological process | genomic imprinting |
GO_1905564 | Biological process | positive regulation of vascular endothelial cell proliferation |
GO_0031017 | Biological process | exocrine pancreas development |
GO_0051146 | Biological process | striated muscle cell differentiation |
GO_0043410 | Biological process | positive regulation of MAPK cascade |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0045725 | Biological process | positive regulation of glycogen biosynthetic process |
GO_0045840 | Biological process | positive regulation of mitotic nuclear division |
GO_0008286 | Biological process | insulin receptor signaling pathway |
GO_0048633 | Biological process | positive regulation of skeletal muscle tissue growth |
GO_0006355 | Biological process | regulation of DNA-templated transcription |
GO_0046628 | Biological process | positive regulation of insulin receptor signaling pathway |
GO_0051897 | Biological process | positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction |
GO_0008284 | Biological process | positive regulation of cell population proliferation |
GO_0046622 | Biological process | positive regulation of organ growth |
GO_0006006 | Biological process | glucose metabolic process |
GO_0040018 | Biological process | positive regulation of multicellular organism growth |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0005615 | Cellular component | extracellular space |
GO_0005576 | Cellular component | extracellular region |
GO_0031093 | Cellular component | platelet alpha granule lumen |
GO_0005158 | Molecular function | insulin receptor binding |
GO_0005159 | Molecular function | insulin-like growth factor receptor binding |
GO_0048018 | Molecular function | receptor ligand activity |
GO_0005179 | Molecular function | hormone activity |
GO_0008083 | Molecular function | growth factor activity |
GO_0005178 | Molecular function | integrin binding |
GO_0043539 | Molecular function | protein serine/threonine kinase activator activity |
GO_0030297 | Molecular function | transmembrane receptor protein tyrosine kinase activator activity |
GO_0005515 | Molecular function | protein binding |
Gene name | IGF2 |
Protein name | Insulin-like growth factor II (IGF-II) (Somatomedin-A) (T3M-11-derived growth factor) [Cleaved into: Insulin-like growth factor II; Insulin-like growth factor II Ala-25 Del; Preptin] Insulin-like growth factor II |
Synonyms | PP1446 |
Description | FUNCTION: The insulin-like growth factors possess growth-promoting activity (By similarity). Major fetal growth hormone in mammals. Plays a key role in regulating fetoplacental development. IGF2 is influenced by placental lactogen. Also involved in tissue differentiation. In adults, involved in glucose metabolism in adipose tissue, skeletal muscle and liver (Probable). Acts as a ligand for integrin which is required for IGF2 signaling . Positively regulates myogenic transcription factor MYOD1 function by facilitating the recruitment of transcriptional coactivators, thereby controlling muscle terminal differentiation (By similarity). Inhibits myoblast differentiation and modulates metabolism via increasing the mitochondrial respiration rate (By similarity). .; FUNCTION: Preptin undergoes glucose-mediated co-secretion with insulin, and acts as a physiological amplifier of glucose-mediated insulin secretion. Exhibits osteogenic properties by increasing osteoblast mitogenic activity through phosphoactivation of MAPK1 and MAPK3. . FUNCTION: Preptin undergoes glucose-mediated co-secretion with insulin, and acts as a physiological amplifier of glucose-mediated insulin secretion. Exhibits osteogenic properties by increasing osteoblast mitogenic activity through phosphoactivation of MAPK1 and MAPK3. . FUNCTION: Preptin undergoes glucose-mediated co-secretion with insulin, and acts as a physiological amplifier of glucose-mediated insulin secretion. Exhibits osteogenic properties by increasing osteoblast mitogenic activity through phosphoactivation of MAPK1 and MAPK3. . |
Accessions | ENST00000695541.1 [P01344-1] P01344 E3UN46 ENST00000381395.5 [P01344-1] ENST00000481781.3 [P01344-1] ENST00000381406.8 [P01344-2] ENST00000418738.2 [P01344-1] B2MUX6 ENST00000434045.6 [P01344-3] ENST00000381392.5 [P01344-2] ENST00000381389.5 [P01344-1] ENST00000416167.7 [P01344-1] |